Details for New Drug Application (NDA): 020490
✉ Email this page to a colleague
NDA 020490 describes ALPHAGAN, which is a drug marketed by Allergan and Abbvie and is included in four NDAs. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the ALPHAGAN profile page.
The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for 020490
| Tradename: | ALPHAGAN |
| Applicant: | Allergan |
| Ingredient: | brimonidine tartrate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020490
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.5% | ||||
| Approval Date: | Mar 13, 1997 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
